Keyphrases
Type 1 Diabetes Mellitus (T1DM)
100%
Myocardial Ischemia-reperfusion Injury
100%
Antidiabetic Drugs
100%
Ischemia-reperfusion Injury
50%
Pioglitazone
50%
Sulfonylurea
50%
Endothelial Dysfunction
25%
Cyclooxygenase-2
25%
Hyperglycemia
25%
Fibrinolysis
25%
Protein Kinase
25%
Clinical Outcomes
25%
Clinical Setting
25%
Protective Effect
25%
Blood Glucose
25%
Myocardial Protection
25%
Ischemic Preconditioning
25%
Rosiglitazone
25%
Thiazolidinediones
25%
Heart Disease
25%
Systemic Inflammation
25%
Prostacyclin
25%
Patients with Diabetes Mellitus
25%
Patients with Diabetes
25%
Hemoglobin A1c (HbA1c)
25%
AMP-activated Protein Kinase
25%
Cytosolic Phospholipase A2 (cPLA2)
25%
Myocardial Infarct Size
25%
Infarct Size
25%
Glyburide
25%
Cardiovascular Outcomes
25%
Pharmacological Preconditioning
25%
Glimepiride
25%
Postconditioning
25%
Protection Mechanism
25%
Lipoxin A4 (LXA4)
25%
Hypercoagulable State
25%
Metformin
25%
Dipeptidyl peptidase-4 (DPP-4)
25%
Platelet Degranulation
25%
GLP-1 Analogue
25%
Heart Stroke
25%
New Antidiabetic Drugs
25%
Sitagliptin
25%
Intracellular cAMP Level
25%
Coronary Collateral Blood Flow
25%
Pharmacology, Toxicology and Pharmaceutical Science
Diabetes Mellitus
100%
Myocardial Ischemia Reperfusion Injury
100%
Anti-Diabetic Medication
100%
Reperfusion Injury
40%
Pioglitazone
40%
Sulfonylurea
40%
Hyperglycemia
20%
Inflammation
20%
Antidiabetic Agent
20%
Cyclooxygenase 2
20%
Heart Disease
20%
Heart Infarction
20%
Endothelial Dysfunction
20%
Rosiglitazone
20%
Thiazolidinedione
20%
Cyclic AMP Dependent Protein Kinase
20%
Prostacyclin
20%
Phospholipase A
20%
Infarction
20%
Glimepiride
20%
Glibenclamide
20%
Lipoxin A
20%
Metformin
20%
Dipeptidyl Peptidase IV Inhibitor
20%
Sitagliptin
20%
Glucagon-Like Peptide-1
20%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
20%
Cerebrovascular Accident
20%